Infinity Pharmaceuticals Inc. (NASDAQ:INFI)’s traded shares stood at 1.45 million during the last session, with the company’s beta value hitting 2.19. At the close of trading, the stock’s price was $3.42, to imply an increase of 0.29% or $0.01 in intraday trading. The INFI share’s 52-week high remains $5.98, putting it -74.85% down since that peak but still an impressive 70.76% since price per share fell to its 52-week low of $1.00. The company has a valuation of $314.54M, with an average of 1.8 million shares in intraday trading volume over the past 10 days and average of 7.47 million shares over the past 3 months.
Analysts have given a consensus recommendation of a Buy for Infinity Pharmaceuticals Inc. (INFI), translating to a mean rating of 1.90. Of 7 analyst(s) looking at the stock, 0 analyst(s) give INFI a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 7 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -$0.13.
Infinity Pharmaceuticals Inc. (NASDAQ:INFI) trade information
After registering a 0.29% upside in the last session, Infinity Pharmaceuticals Inc. (INFI) has traded red over the past five days. The stock hit a weekly high of 3.74 this Thursday, 09/16/21, jumping 0.29% in its intraday price action. The 5-day price performance for the stock is -7.07%, and 10.32% over 30 days. With these gigs, the year-to-date price performance is 61.32%. Short interest in Infinity Pharmaceuticals Inc. (NASDAQ:INFI) saw shorts transact 3.9 million shares and set a 2.71 days time to cover.
Analysts on Wall Street suggest a consensus price target of $9.29, implying an increase of 63.19% to the stock’s current value. The extremes give us $4.00 and $14.00 for target low and target high price respectively. As such, INFI has been trading -309.36% off suggested target high and -16.96% from its likely low.
Infinity Pharmaceuticals Inc. (INFI) estimates and forecasts
Looking at statistics comparing Infinity Pharmaceuticals Inc. share performance against respective industry, we note that the company has underperformed competitors. Infinity Pharmaceuticals Inc. (INFI) shares are 1.79% up over the last 6 months, with its year-to-date growth rate lower than industry average at 17.65% against 18.10%. Revenue is forecast to grow 18.80% this quarter before jumping 12.50% for the next one. The rating firms project that company’s revenue will grow 0.10% compared to the previous financial year.
Revenue forecast for the current quarter as set by 5 analysts is $530k. Meanwhile, for the quarter ending Dec 2021, a total of 5 analyst(s) estimate revenue growth to $540k.Earnings reports from the last fiscal year show that sales brought in $496k and $436k respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 6.90% before jumping 23.90% in the following quarter.
Infinity Pharmaceuticals Inc. has its next earnings report out between November 08 and November 12. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Infinity Pharmaceuticals Inc. has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.
Infinity Pharmaceuticals Inc. (NASDAQ:INFI)’s Major holders
Infinity Pharmaceuticals Inc. insiders hold 2.17% of total outstanding shares, with institutional holders owning 55.96% of the shares at 57.20% float percentage. In total, 55.96% institutions holds shares in the company, led by BVF Inc. As of Mar 30, 2021, the company held over 8.38 million shares (or 9.46% of shares), all amounting to roughly $27.08 million.
The next major institution holding the largest number of shares is Consonance Capital Management LP with 6.58 million shares, or about 7.42% of shares outstanding. As of the market price on Mar 30, 2021, these shares were worth $21.24 million.
We also have Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund as the top two Mutual Funds with the largest holdings of the Infinity Pharmaceuticals Inc. (INFI) shares. Going by data provided on Mar 30, 2021, Vanguard Total Stock Market Index Fund holds roughly 2.06 million shares. This is just over 2.32% of the total shares, with a market valuation of $6.64 million. Data from the same date shows that the other fund manager holds a little less at 1.38 million, or 1.55% of the shares, all valued at about 4.45 million.